ERR2598269
fetal · fetal
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- fetal
- cancer_type_detailed
- —
- subtype
- fetal
- cancer_type
- fetal
- subtype
- fetal
- sex
- fetal
- race
- fetal
- fetal_age_forebrain
- 24
- umap1_2d
- -2.34299868
- umap2_2d
- 5.075767157
- umap1_3d
- 1.198259021
- umap2_3d
- 0.661810843
- umap3_3d
- 0.15229296
- dataset
- fetal
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.460
- COAGULATION+0.450
- INFLAMMATORY_RESPONSE+0.430
- KRAS_SIGNALING_DN+0.400
- MYOGENESIS+0.380
- INTERFERON_ALPHA_RESPONSE+0.360
- PANCREAS_BETA_CELLS+0.360
- COMPLEMENT+0.350
- OXIDATIVE_PHOSPHORYLATION+0.350
- KRAS_SIGNALING_UP+0.330
Top 10 suppressed
- G2M_CHECKPOINT-0.570
- E2F_TARGETS-0.550
- MITOTIC_SPINDLE-0.510
- MYC_TARGETS_V1-0.500
- MYC_TARGETS_V2-0.490
- WNT_BETA_CATENIN_SIGNALING-0.430
- NOTCH_SIGNALING-0.380
- UNFOLDED_PROTEIN_RESPONSE-0.370
- DNA_REPAIR-0.340
- MTORC1_SIGNALING-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598335 | fetal | fetal | 0.948 |
| 2 | ERR2598329 | fetal | fetal | 0.946 |
| 3 | ERR2598280 | fetal | fetal | 0.944 |
| 4 | ERR2598266 | fetal | fetal | 0.924 |
| 5 | MDT-AP-1254 | Med | Medulloblastoma | 0.916 |
| 6 | MDT-AP-2579 | Med | Medulloblastoma | 0.908 |
| 7 | ERR2598268 | fetal | fetal | 0.905 |
| 8 | 9075936e-cc58-4740-abf4-1c733abb3d9f | — | — | 0.899 |
| 9 | ERR2598267 | fetal | fetal | 0.898 |
| 10 | ERR2598288 | fetal | fetal | 0.889 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.460 | Idelalisib | — uncovered |
| COAGULATION | 0.450 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.430 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.400 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.380 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.360 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.330 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.320 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.310 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.290 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.290 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.280 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.270 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.270 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.270 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.220 | Inavolisib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |